Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10830637 | 0.75 | TSHR (0.32) | TSHRNPSR1LMNAPDK2PDK4 | |
| SCHEMBL13956572 | 0.73 | — | — | |
| SCHEMBL12132430 | 0.73 | — | — | |
| SCHEMBL14446948 | 0.70 | — | — | |
| SCHEMBL2999710 | 0.69 | TSHR (0.31) | TSHR | |
| SCHEMBL3119128 | 0.68 | CRBN (0.42) | TSHRNPSR1LMNA | |
| SCHEMBL2689498 | 0.67 | — | — | |
| SCHEMBL10391507 | 0.67 | TSHR (0.33) | TSHRNPSR1LMNA | |
| SCHEMBL10391506 | 0.67 | TSHR (0.33) | TSHRNPSR1LMNA | |
| SCHEMBL8088292 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618844-B2 | Cancer | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-05-05 | — | — | US | claimed |
| US-20230068371-A1 | CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-03-02 | — | — | US | claimed |
| EP-4090978-A1 | CANCER | Imperial College Innovations Limited (GB) | 2022-11-23 | — | — | EP | claimed |
| CN-115280150-A | Cancer treatment | 帝国学院创新有限公司 | 2022-11-01 | — | — | CN | claimed |
| WO-2021144589-A1 | CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2021-07-22 | — | — | WO | claimed |
| CN-102409372-A | Method of electroplating silver strike over nickel | ROHM & HAAS ELECT MAT | 2012-04-11 | — | — | CN | claimed |
| US-20070078177-A1 | METHODS AND COMPOSITIONS FOR TREATING NON AGE RELATED HEARING IMPAIRMENT IN A SUBJECT | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2007-04-05 | — | — | US | claimed |
| CN-1170963-C | Cyanide-free monovalent copper eletroplating solutions | ���ɶ��ؼ����� | 2004-10-13 | — | — | CN | claimed |
| EP-1009869-B1 | CYANIDE-FREE MONOVALENT COPPER ELECTROPLATING SOLUTIONS | LEARONAL INC (US) | 2002-10-02 | — | — | EP | claimed |
| CN-1256722-A | Cyanide-free monovalent copper eletroplating solutions | LEARONAL INC (US) | 2000-06-14 | — | — | CN | claimed |
| US-5750018-A | Cyanide-free monovalent copper electroplating solutions | LEARONAL, INC. (US) | 1998-05-12 | — | — | US | claimed |
| US-4126524-A | REACTION PRODUCT OF SILVER SALT AND PYRROLIDINE-2,5-DIONE OR PYRROLINE-2,5-DIONE | TECHNIC, INC. (US) | 1978-11-21 | — | — | US | claimed |
| US-12618844-B2 | Cancer | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | ASTROCYTE PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4329773-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | Astrocyte Pharmaceuticals, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117241803-A | Purine nucleosides, intermediates and methods of making the same | 阿斯特罗赛特制药公司 | 2023-12-15 | — | — | CN | disclosed |
| US-4278514-A | Bright palladium electrodeposition solution | TECHNIC, INC. (US) | 1981-07-14 | — | — | US | disclosed |
| US-4246077-A | SILVER COMPLEX OF 3-PYRROLINE-2,5-DIONE OR PYRROLIDINE-2,5-DIONE | TECHNIC, INC. (US) | 1981-01-20 | — | — | US | disclosed |
| US-4126524-A | REACTION PRODUCT OF SILVER SALT AND PYRROLIDINE-2,5-DIONE OR PYRROLINE-2,5-DIONE | TECHNIC, INC. (US) | 1978-11-21 | — | — | US | disclosed |
| US-4025512-A | ANTIDEPRESSANTS | ABBOTT LABORATORIES (US) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618844-B2 | Cancer | FABP2, CA12, CA13 | TSHR 1899/4885NPSR1 3289/4885LMNA 1919/4885 |
| US-20240368164-A1 | PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF | NUDT1, PNP, UMPS | TSHR 4088/4885NPSR1 1395/4885LMNA 400/4885 |
| US-20070078177-A1 | METHODS AND COMPOSITIONS FOR TREATING NON AGE RELATED HEARING IMPAIRMENT IN A SUBJECT | OTC, CLN6, CHAT | TSHR 4546/4885NPSR1 1026/4885LMNA 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.